

Evidence generation and reproducibility in cell and gene therapy research: A call to action

The emergence of new cell and gene-based therapies (CGTs) utilizing innovative technologies has recently intensified. Long-standing efforts in publicly funded biomedical research have resulted in breakthrough therapeutic approaches for patients with devastating and life-threatening diseases. Transformative gene-based therapeutic tools include human genome editing technologies, refined transposon systems, and synthetic immunoreceptors, such as chimeric antigen receptor (CAR) T cell and natural killer cell engineered immunotherapies. Cancer has been a leading disease target, with the treatment of B cell malignancies yielding compelling clinical outcomes, resulting in the regulatory approval of several CAR T cell therapies.¹ Concurrently, intensive research on solid tumor indications is underway.² Similarly, rare diseases are prominent targets for gene therapy and gene editing technologies.³ Founded on these scientific advances, next-generation CGTs are expected to transform into treatment options for a wider spectrum of conditions.^{4,5} Moreover, while these treatments, to-date, target mostly patients with advanced illnesses, future therapies may be introduced at earlier disease stages, even as primary therapeutic options. Here, we highlight some of the obstacles inherent in CGT evidence generation and research reproducibility and recommend concerted actions on how they can be overcome.

Developers, regulators, funders and payers involved in the development and delivery of next-generation CGTs need to rely on robust evidence of their benefits and risks to support decision making⁶ and ensure their translation from promising discoveries to effective therapeutics.⁷ Inadequate evidence on their comparative efficacy has led several CGTs to be withdrawn from the European Union (EU) market mainly due to inability to satisfy national reimbursement requirements.⁸ This is due, in part, to certain unique attributes of CGTs such as heterogeneity in treatment response and toxicities, targeting rare diseases with low patient accrual and lack of suitable comparators in clinical trials, and the need for long-term safety and efficacy follow up studies, among others.⁹ Importantly, the mode of action for gene therapies, in many cases, relies on introducing permanent changes to human cells and tissues, which, in turn, increases the risk of unforeseen and delayed adverse events. As a result, regulatory agencies require developers to conduct long-term patient follow-up, amounting to 15 years of observation, with the right infrastructure in place to collect longitudinal patient data, e.g., through patient registries.^{10,11} Additionally, CGTs are rarely readily available as “off the shelf” therapies and must be customized, leading to high development costs; thus, accessibility becomes an issue for patients and health care providers.

It is also acknowledged that pre-clinical testing of CGTs has, in some instances, limited capability for generating informative evidence. *In vivo* models in highly inbred, specialized mouse strains may not

adequately reproduce features of the target patient population.¹² Often, normal donor cells are employed to obtain pre-clinical evidence on the safety and efficacy of genetic engineering strategies, which may not accurately reflect later findings in treated patients.¹² Additionally, some pre-clinical studies, such as toxicokinetics and mode of action, are technically difficult to perform for CGTs.⁹ The use of models that incorporate human cells and tissues and exhibit highly differentiated features (e.g., organoids, organs-on-chips) could be beneficial for preclinical validation efforts.¹³ For instance, patient-derived organoids that recapitulate clinically relevant features of organ pathophysiology may be useful to test delivery, predict toxicities, or assert the validity of early clinical findings of a gene therapy approach,¹⁴ particularly for rare genetic disorders. Transcriptomic technologies would be beneficial for in-depth investigation and validation of such organoid models.¹⁵ Crucially, ethical concerns associated with deployment of organoids and gene editing approaches require continuing deliberations.^{16,17}

Ideally, CGT clinical trial design would consider the harmonization of outcome measures and their reporting to facilitate comparisons across studies and the pooling of data needed for statistical meta-analysis.¹⁸ Engaging statisticians in the earliest phases of clinical development is essential in assuring appropriate study design. Some new technologies may require preliminary studies with smaller patient cohorts to demonstrate their feasibility, e.g., phase 0/1 trials, including the observation of unexpected toxicities, identification of patient populations most likely to benefit, and an understanding of key barriers for implementation.¹⁹ This approach is compatible with improving trial enrollment in subsequent larger clinical studies. It is also important to ensure that socioeconomic and racial/ethnic disparities are considered in CGT trial design and patient enrollment.²⁰ Patient advocates can play an active role in improving patient recruitment and retention in CGTs clinical trials.²¹

Consistent and high-quality evidence on the health benefits of a new therapeutic modality is not only needed to justify regulatory licensing but also health insurance coverage and reimbursement decisions.²² CGT prices are often elevated on the basis of their high development costs and anticipated curative value as a one-time treatment. Additionally, the clinical benefits of curative therapies are associated with significant uncertainties, complicating their appraisal using traditional economic evaluation methods such as cost-effectiveness analysis, which may require methodological recalibration.²³ Ensuring and monitoring long-term data collection through post-approval studies and surveillance as a regulatory prerequisite can help overcome this limitation.²⁴ Where feasible, data should be collected and curated to facilitate access and analysis by independent investigators. These efforts could also benefit from initiatives such as the National



Patient-Centered Clinical Research Network (<https://pcor-net.org/>), the National Institutes of Health Collaboratory (<https://commonfund.nih.gov/hcscollaboratory>), or the European Data Analytics and Real World Interrogation Network (DARWIN) initiative to capture real world experiences. While the exploration of new alternative financing mechanisms and innovative insurance schemes for CGTs are certainly welcome,²² health technology assessments should be flexible enough and adapt to evidence uncertainties associated with the potential curative benefits of CGTs for serious or life threatening illnesses when no alternative therapies exist. Given all these challenges, robust scientific evidence based on reproducible and replicable research is critically needed to inform decision-making throughout the CGT life cycle.

In summary, the development of highly effective CGTs offers hope to millions of patients with severe and previously incurable diseases. However, providing an evidence base for their effective and safe deployment must be a priority. Goals for optimal product development should include: (1) avoiding marketed products being withdrawn by manufacturers or regulators due to lapses in evidence generation; (2) systematic monitoring for potentially new and/or delayed adverse events not identified during clinical research phases (especially in orphan diseases with small pre-authorization studies); and (3) limiting the instances in which post-approval real-world evidence fails to confirm therapeutic benefits.²⁵ Additionally, the high upfront costs of some CGTs and their reimbursement challenges could potentially jeopardize their continued use and undermine confidence in the broader therapeutic category. In a field with such strong scientific prospects but also high degree of vulnerability due to limited clinical experience and evidence, transparency throughout research and development stages is key. Some of these issues have been raised in the International Society for Stem Cell Research (ISSCR) guidelines governing clinical translation of novel stem cell-based therapeutics²⁶ intended to protect patients against false hopes or potential harms that can result from unproven stem cell interventions.²⁷

We call for increased attention to methodological improvements in pre-clinical and clinical study designs, including robust data collection and evaluation, together with the complete disclosure of protocols and publication of results, be they positive or negative. Experimental replication/validation should be achieved at the pre-clinical stage to maximize the prospects of successful clinical translation. This will require a change in culture of the scientific ecosystem, including the need to both conduct and publish the findings of meaningful attempts to reproduce results (that is, computational reproducibility from the same data) or to replicate findings through new sets of experiments, to either strengthen or challenge current evidence.²⁸ Assessing both the quality of evidence and experimental replicability requires accurate reporting of the original study's methods and a sample population that can be accessed or recreated,²⁹ including access to deidentified patient data to underpin secondary analyses.³⁰ Multiple stakeholders, particularly research funding agencies and academic institutions, will be required to support these efforts and provide tools and infrastructure, ultimately

enabling researchers to achieve these goals.²⁸ An investment in evidence generation and reproducibility of results will pay off with improved efficiency in the development and application of CGTs and will eventually save resources. The multidisciplinary approaches discussed here could strengthen evidence, reduce uncertainties, and diminish potential biases, thus enhancing clinical, regulatory, and payers decision making. This proposed blueprint for CGTs relies on rigorous research to meet pressing clinical needs while generating the societal support required for delivering these promising therapies across the globe.

ACKNOWLEDGMENTS

The views expressed in this article are those of the authors, who are responsible for its content, and do not necessarily represent the views of the agencies or organizations with which the authors are affiliated. No statement in this report should be construed as an official position of the Agency for Healthcare Research and Quality (AHRQ) or the US Department of Health and Human Services. The work of J.D.W. is supported in part by US NIH/NCI Cancer Center Support grant P30 CA008748, NIH/NCI grant R01 CA056821, Swim Across America, the Ludwig Institute for Cancer Research, the Ludwig Center for Cancer Immunotherapy at Memorial Sloan Kettering, the Cancer Research Institute, and the Parker Institute for Cancer Immunotherapy. The work of M.A.C. is supported by US NIH grant R35CA210087. M.A.H. is co-chair of the WHO Expert Advisory Group on Developing Global Standards for Governance and Oversight of Human Genome Editing. The work of A.T. is supported by US NIH grant R01 HL134664, and the Marriott Family Foundation. M.L. is supported in part by grants to Health Data Research UK and DATA-CAN, the UK's Health Data Research Hub for Cancer.

COMPETING INTERESTS

N.C.A. is a member of the Boards of Directors for Novartis, Charles River Laboratories, and Maze Therapeutics as well as a member of the Scientific Advisory Board for Dyne Therapeutics. M.K.B. is on the advisory board of Bluebird Bio and Turnstone, founder member of Tessa Therapeutics and Marker Therapeutics, on the Scientific Advisory Board of Tessa Therapeutics, Marker Therapeutics, Allogene, Walking Fish, Memgen, KUUR, Bellicum Pharmaceuticals, Tscan, Poseida, and Abintus, and reports stock options for Marker Therapeutics, Allogene, and Walking Fish. M.A.C. is a co-founder of CytoImmune Therapeutics and Precision Technologies, a shareholder of Beigene, and chair or member of the scientific advisory boards of CBMG, OncoC4, Imugene, and Cytovia Therapeutics. H.C. is a member of the board of directors of Roche and Genentech, co-founder of Xilis and Surrozen, and SAB member of Volastra, Decibel, and Genentech. G.Q.D. holds patents related to pluripotent stem cells and hematopoietic derivatives and holds equity and receives consulting fees from 28/7 Therapeutics. L.M.E. is a consultant for Oncohost, the Data Safety Monitoring Committee for Fibrogen, and New Beta-Innovations. S.G. has patent applications in the field of T cell and gene-modified T cell therapy for cancer; is a consultant for Catamaran Bio, Nektar Therapeutics, and TESSA Therapeutics; is on the Scientific

Advisory Board of Tidal; and is a DSMB member of Immmatics. M.A.H. is a member of the Boards of Directors for Alnylam Pharmaceuticals. D.E.I. is a board member of Emulate Inc., Boa Biomedical Inc., and Pareto Bio Inc., chairs the scientific advisory boards of Emulate and Boa, and holds equity in Emulate, Boa, Pareto Bio, and FreeFlow Medical Devices Inc.; he also consults for Fulcrum Therapeutics and F. Hoffman La Roche. A.R.K. is a member of the Board of Directors of Stoke Therapeutics, a member of the Scientific Advisory Boards of Stoke Therapeutics, Skyhawk Therapeutics, Envi-sagenics Bioanalytics, Silagene, and Autoimmunity BioSolutions, and a consultant for Biogen. M.V.M. is an inventor on patents related to adoptive cell therapies held by Massachusetts General Hospital and University of Pennsylvania (some licensed to Novartis), holds equity in TCR2 and Century Therapeutics, and has served as a consultant for multiple companies involved in cell therapies. S.A.T. has received, in the past 3 years, remuneration for consulting and membership of Scientific Advisory Boards at Roche, Genentech, Biogen, GlaxoSmithKline, and ForeSite Labs. A.T. is co-founder of Rion LLC. F.D.U. is a scientific co-founder of Tune Therapeutics and an advisor to GSK. D.A.W. reports prior research funding from Bluebird Bio and Orchard Therapeutics; is on the Scientific Advisory Board of Geneception, Beam Therapeutics, and Orchard Therapeutics (SAB ended 5/20); is on the Insertion Site Advisory Board of Bluebird Bio and Biomarin; is co-founder of Alerion Biosciences (now licensed to Avro Bio) and Orchard Therapeutics; received payment in the past through a BCH institutional licensing agreement, with potential for future royalty/milestone income from Bluebird Bio, Orchard Therapeutics, and Alerion Biosciences and licensed certain IP relevant to hemoglobinopathies to Bluebird Bio. D.A.W. is on the steering Committee of Novartis ETB115E2201 (advisory fees donated to NAPAAC). J.D.W. is a Consultant for Amgen, Apricity, Ascentage Pharma, Arsenal IO, Astellas, AstraZeneca, Bayer, Bicara Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Dragonfly, Eli Lilly, F Star, Georgiamune, Idera, Imvaq, Kyowa Hakko Kirin, Maverick Therapeutics, Merck, Neon Therapeutics, Psioxus, Recepta, Tizona, Trieza, Truvax, Trishula, Sellas, Surface Oncology, Syndax, Syntalogic, and Werewolf Therapeutics. J.D.W. reports grant/research support from Bristol Myers Squibb and Sephora and has Equity in Tizona Pharmaceuticals, Adaptive Biotechnologies, Imvaq, Beigene, Linneaus, Apricity, Arsenal IO, Georgiamune, Trieza and Maverik Therapeutics. M.L. has received an unrestricted educational grant from Pfizer for research unrelated to this work and honoraria from Pfizer, EMD Serono, Roche, and Carnall Farrar unrelated to this work. C.J.T. has served on the scientific advisory boards of ArsenalBio, Caribou Biosciences, Century Therapeutics, Eureka Therapeutics, Myeloid Therapeutics, Precision Biosciences, and T-CURX; has acted as an *ad hoc* consultant of Allogene, Amgen, AstraZeneca, Asher Bio, Nektar Therapeutics and PACT Pharma; has stock/options in ArsenalBio, Caribou Biosciences, Eureka Therapeutics, Myeloid Therapeutics, and Precision Biosciences; has received research funding from AstraZeneca, Juno Therapeutics/BMS, Nektar Therapeutics, and TCR2 Therapeutics; and has the right to receive royalties from Fred Hutch for a patent licensed to Juno Therapeutics/BMS. M.A., A.A., F.R.A., S.E.B., A.S.B., M.C., E.C., V.J.D.,

H.V.F., L.S.B.G., D.B.K., P.M., C.L.M., R.I.P., J.L.R., G.B., and J.P.A.I. declare no competing interests in relation to this work.

Mohamed Abou-el-Enein,^{1,2} Aris Angelis,^{3,4} Frederick R. Appelbaum,^{5,6} Nancy C. Andrews,⁷ Susan E. Bates,⁸ Arlene S. Bierman,⁹ Malcolm K. Brenner,¹⁰ Marina Cavazzana,^{11,12} Michael A. Caligiuri,¹³ Hans Clevers,^{14,15} Emer Cooke,¹⁶ George Q. Daley,^{17,18} Victor J. Dzau,¹⁹ Lee M. Ellis,²⁰ Harvey V. Fineberg,²¹ Lawrence S.B. Goldstein,^{22,23} Stephen Gottschalk,²⁴ Margaret A. Hamburg,^{25,26} Donald E. Ingber,^{17,18,27,28} Donald B. Kohn,^{29,30} Adrian R. Krainer,³¹ Marcela V. Maus,^{18,32} Peter Marks,³³ Christine L. Mummery,³⁴ Roderic I. Pettigrew,³⁵ Joni L. Rutter,³⁶ Sarah A. Teichmann,^{37,38} Andre Terzic,^{39,40} Fyodor D. Urnov,⁴¹ David A. Williams,^{17,18,42} Jedd D. Wolchok,^{43,44} Mark Lawler,⁴⁵ Cameron J. Turtle,^{5,6} Gerhard Bauer,⁴⁶ and John P.A. Ioannidis^{47,48}

¹Division of Medical Oncology, Department of Medicine and Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; ²Joint USC/CHLA Cell Therapy Program, University of Southern California and Children's Hospital Los Angeles, Los Angeles, CA, USA; ³Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK; ⁴Department of Health Policy and LSE Health, London School of Economics and Political Science, London, UK; ⁵Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ⁶Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA; ⁷Department of Pharmacology and Cancer Biology and Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA; ⁸Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY, USA; ⁹Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, Rockville, MD, USA; ¹⁰Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA; ¹¹Biotherapy Department, Necker Children's Hospital, Assistance Publique-Hopitaux de Paris, Paris, France; ¹²Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Quest, INSERM, Paris, France; ¹³Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Duarte, CA, USA; ¹⁴Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), Utrecht, the Netherlands; ¹⁵University Medical Center Utrecht, Utrecht, the Netherlands; ¹⁶European Medicines Agency, Amsterdam, the Netherlands; ¹⁷Boston Children's Hospital, Boston, MA, USA; ¹⁸Harvard Medical School, Boston, MA, USA; ¹⁹US National Academy of Medicine, Washington, DC, USA; ²⁰Department of Surgical Oncology and Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ²¹Gordon and Betty Moore Foundation, Palo Alto, CA, USA; ²²Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA; ²³Sanford Consortium for Regenerative Medicine, La Jolla, CA, USA; ²⁴Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA; ²⁵American Association for the Advancement of Science (AAAS), Washington, DC, USA; ²⁶National Academy of Medicine, Washington, DC, USA; ²⁷Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA; ²⁸Harvard John A. Paulson School of Engineering and Applied Sciences, Cambridge, MA, USA; ²⁹Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of

Medicine, University of California, Los Angeles, Los Angeles, CA, USA; ³⁰The Eli & Edith Broad Center of Regenerative Medicine & Stem Cell Research, University of California, Los Angeles, Los Angeles, CA, USA; ³¹Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA; ³²Massachusetts General Hospital Cancer Center, Charlestown, MA, USA; ³³Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA; ³⁴Department of Anatomy and Embryology, Leiden University Medical Center, Leiden, the Netherlands; ³⁵ENMED, Colleges of Medicine and Engineering, Texas A&M University, Houston, TX, USA; ³⁶National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA; ³⁷Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK; ³⁸Theory of Condensed Matter, Cavendish Laboratory, University of Cambridge, JJ Thomson Ave, Cambridge, UK; ³⁹Center for Regenerative Medicine, Mayo Clinic, Rochester, MN, USA; ⁴⁰Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA; ⁴¹Innovative Genomics Institute, University of California, Berkeley, CA, USA; ⁴²Division of Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA; ⁴³Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁴⁴Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; ⁴⁵Patrick G Johnston Centre for Cancer Research, Faculty of Medicine, Health and Life Sciences, Queen's University Belfast, Belfast, UK; ⁴⁶Institute for Regenerative Cures, University of California, Davis, Sacramento, CA, USA; ⁴⁷Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford, CA, USA; ⁴⁸Department of Epidemiology and Population Health and Department of Biomedical Data Sciences, Stanford University, Stanford, CA, USA

Correspondence: Mohamed Abou-el-Enein, Division of Medical Oncology, Department of Medicine and Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

E-mail: abouelenein@med.usc.edu

<https://doi.org/10.1016/j.omtm.2021.06.012>

REFERENCES

- Elsallab, M., Levine, B.L., Wayne, A.S., and Abou-El-Enein, M. (2020). CAR T-cell product performance in haematological malignancies before and after marketing authorisation. *Lancet Oncol.* *21*, e104–e116.
- Fucà, G., Reppel, L., Landoni, E., Savoldo, B., and Dotti, G. (2020). Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors. *Clin. Cancer Res.* *26*, 2444–2451.
- Tambuyzer, E., Vandendriessche, B., Austin, C.P., Brooks, P.J., Larsson, K., Miller Needleman, K.I., Valentine, J., Davies, K., Groft, S.C., Preti, R., et al. (2020). Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. *Nat. Rev. Drug Discov.* *19*, 93–111.
- Cavazzana, M., Bushman, F.D., Miccio, A., André-Schmutz, I., and Six, E. (2019). Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges. *Nat. Rev. Drug Discov.* *18*, 447–462.
- Feucht, J., and Abou-El-Enein, M. (2020). Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies. *Mol. Ther.* *28*, 2108–2110.
- Abou-El-Enein, M., Cathomen, T., Ivics, Z., June, C.H., Renner, M., Schneider, C.K., and Bauer, G. (2017). Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment. *Cell Stem Cell* *21*, 427–430.
- Yamada, S., Behfar, A., and Terzic, A. (2021). Regenerative medicine clinical readiness. *Regen. Med.* *16*, 309–322.
- Abou-El-Enein, M., Elsanhoury, A., and Reinke, P. (2016). Overcoming Challenges Facing Advanced Therapies in the EU Market. *Cell Stem Cell* *19*, 293–297.
- Elsallab, M., Bravery, C.A., Kurtz, A., and Abou-El-Enein, M. (2020). Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals. *Mol. Ther. Methods Clin. Dev.* *18*, 269–279.
- Abou-El-Enein, M., Grainger, D.W., and Kili, S. (2018). Registry Contributions to Strengthen Cell and Gene Therapeutic Evidence. *Mol. Ther.* *26*, 1172–1176.
- US Food and Drug Administration (2020). Long Term Follow-Up After Administration of Human Gene Therapy Products <https://www.fda.gov/media/113768/download>.
- Ioannidis, J.P.A., Kim, B.Y.S., and Trounson, A. (2018). How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation. *Nat. Biomed. Eng.* *2*, 797–809.
- Schwank, G., Koo, B.-K., Sasselli, V., Dekkers, J.F., Heo, I., Demircan, T., Sasaki, N., Boymans, S., Cuppen, E., van der Ent, C.K., et al. (2013). Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. *Cell Stem Cell* *13*, 653–658.
- Clevers, H. (2016). Modeling Development and Disease with Organoids. *Cell* *165*, 1586–1597.
- Aldridge, S., and Teichmann, S.A. (2020). Single cell transcriptomics comes of age. *Nat. Commun.* *11*, 4307.
- Bredenoord, A.L., Clevers, H., and Knoblich, J.A. (2017). Human tissues in a dish: The research and ethical implications of organoid technology. *Science* *355*, eaaf9414.
- Doudna, J.A. (2020). The promise and challenge of therapeutic genome editing. *Nature* *578*, 229–236.
- Abou-El-Enein, M., and Hey, S.P. (2019). Cell and Gene Therapy Trials: Are We Facing an 'Evidenc Crisis'? *EClinicalMedicine* *7*, 13–14.
- Stadtmauer, E.A., Fraietta, J.A., Davis, M.M., Cohen, A.D., Weber, K.L., Lancaster, E., Mangan, P.A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020). CRISPR-engineered T cells in patients with refractory cancer. *Science* *367*, eaba7365.
- Kent, D.M., Rothwell, P.M., Ioannidis, J.P., Altman, D.G., and Hayward, R.A. (2010). Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. *Trials* *11*, 85.
- Bauer, G., Abou-El-Enein, M., Kent, A., Poole, B., and Forte, M. (2017). The path to successful commercialization of cell and gene therapies: empowering patient advocates. *Cytotherapy* *19*, 293–298.
- Hampson, G., Towse, A., Pearson, S.D., Dreitlein, W.B., and Henshall, C. (2018). Gene therapy: evidence, value and affordability in the US health care system. *J. Comp. Eff. Res.* *7*, 15–28.
- Angelis, A., Naci, H., and Hackshaw, A. (2020). Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies. *Pharmacoeconomics* *38*, 1297–1308.
- Fritsche, E., Elsallab, M., Schaden, M., Hey, S.P., and Abou-El-Enein, M. (2019). Post-marketing safety and efficacy surveillance of cell and gene therapies in the EU: A critical review. *Cell Gene Ther. Insights* *5*, 1505–1521.
- Beaver, J.A., and Pazdur, R. (2021). "Dangling" Accelerated Approvals in Oncology. *N Engl J Med.* *384*, e68.
- Lovell-Badge, R., Anthony, E., Barker, R.A., Bubela, T., Brivanlou, A.H., Carpenter, M., Charo, R.A., Clark, A., Clayton, E., Cong, Y., et al. (2021). ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update. *Stem Cell Reports* *16*, 1398–1408.
- Bauer, G., Elsallab, M., and Abou-El-Enein, M. (2018). Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions. *Stem Cells Transl. Med.* *7*, 676–685.
- National Academies of Sciences Engineering and Medicine (2019). Reproducibility and Replicability in Science (National Academies Press).
- Munafò, M.R., Nosek, B.A., Bishop, D.V.M., Button, K.S., Chambers, C.D., Percie du Sert, N., Simonsohn, U., Wagenmakers, E.-J., Ware, J.J., and Ioannidis, J.P.A. (2017). A manifesto for reproducible science. *Nat Hum Behav.* *1*, 0021.
- Fortunato, A., Grainger, D.W., and Abou-El-Enein, M. (2018). Enhancing patient-level clinical data access to promote evidence-based practice and incentivize therapeutic innovation. *Adv. Drug Deliv. Rev.* *136–137*, 97–104.